spacer
home > ict > winter 2009 > from dumb to smart
PUBLICATIONS
International Clinical Trials

From Dumb to Smart

BACKGROUND

The business fundamentals of conducting clinical research have changed dramatically over the last few years. Although not quite as well-publicised as the recent events in world financial markets, the fundamentals of the industry have steadily eroded. Clinical trials are more expensive, take longer to run, and patient recruitment is harder than ever, to give just a few examples.

Even more worrying is the fact that the industry has been content to operate in the dark, with few objective metrics about the convoluted internal operations critical to planning and conducting clinical trials. For example, the Six Sigma methodologies that can be applied to the clinical development process have only recently been recognised by the industry, despite the fact that Six Sigma provides objective criteria that helps to measure the value of decisions. These decisions commit hundreds of millions of dollars to development programmes.

Furthermore, job cuts are occurring with increasing regularity, as are dramatic outsourcing arrangements and billion-dollar acquisitions. Unfortunately, while these big announcements garner a lot of attention, the actions often obscure the need to improve the efficiency and effectiveness of day-to-day clinical operations. In fact, the decisions related to crucial development activities that determine the successes of specific clinical programmes and the overall health of the industry are often overlooked.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Edward Seguine is General Manager, Trial Planning Solutions, at Medidata Solutions, and is responsible for strategy development and execution. As a member of the senior management team at Medidata, Ed oversees all development, implementation and commercialisation activities for Medidata CRO Contractor, Medidata Designer, Medidata Grants Manager and the proprietary benchmark data these products rely on. Previously, Ed served as CEO of Fast Track Systems Inc, after moving from Eli Lilly, where he was instrumental in establishing both e.Lilly and Lilly Ventures. Ed is active in CDISC as the chair-elect of the Industry Advisory Board, a non-voting member of the CDISC board, and Financial Oversight Committee. In addition, he has written several articles and is a periodic speaker at industry events. Ed earned his BBA from Brigham Young University and MBA from Indiana University.
spacer
Edward Seguine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo keeps growing in the first quarter of 2019

Maintaining its accomplished operations from Ataturk and Istanbul airports as "Dual Hub", the global brand of Turkish Cargo continued its strong growth momentum during the first quarter of the year despite the shrinkage of the global air cargo sector.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement